Johnson & Johnson on Tuesday said its third-quarter earnings rose on strong demand for its medical devices, including its Cypher stent, but sales of prescription drugs fell amid competition from cheaper generics.
*For more on this story,
read the full Reuters article.
The company also said its considering alternatives to its planned $25.4 billion buy of Guidant Corp., although it expects regulatory approval this month for the deal.
*For more on this story,
read the full Reuters article.